» Articles » PMID: 32164085

[Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia]

Overview
Specialty Pulmonary Medicine
Date 2020 Mar 13
PMID 32164085
Citations 120
Affiliations
Soon will be listed here.
Abstract

At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.

Citing Articles

Chloroquine: A Potential Drug in the COVID-19 Scenario.

Singh R, Vijayan V Trans Indian Natl Acad Eng. 2024; 5(2):399-410.

PMID: 38624400 PMC: 7275976. DOI: 10.1007/s41403-020-00114-w.


Interplay of host and viral factors in inflammatory pathway mediated cytokine storm during RNA virus infection.

Chaudhary R, Meher A, Krishnamoorthy P, Kumar H Curr Res Immunol. 2023; 4:100062.

PMID: 37273890 PMC: 10238879. DOI: 10.1016/j.crimmu.2023.100062.


Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles.

Manuja A, Chhabra D, Kumar B Arab J Chem. 2022; 16(2):104468.

PMID: 36466721 PMC: 9710101. DOI: 10.1016/j.arabjc.2022.104468.


Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

Sahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir N, Sancar S J Pharm Sci. 2022; 111(10):2652-2661.

PMID: 35691607 PMC: 9181835. DOI: 10.1016/j.xphs.2022.06.004.


Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.

Gao X, Jing X, Wang J, Zheng Y, Qiu Y, Ji H Chem Biol Interact. 2022; 361:109954.

PMID: 35469826 PMC: 9023373. DOI: 10.1016/j.cbi.2022.109954.